Envisagenics, Inc., a New York based biotechnology company, announced today that it was awarded a Small Business Innovation Research (SBIR) Phase II grant from the National Institutes of Health (NIH). This grant will provide $1.5 million over two years for Envisagenics’ ...
Read More »Envisagenics closes $2.35M seed round and launches SpliceCore Platform for identifying RNA targets from splicing errors
Envisagenics, Inc., a biotechnology company that applies Artificial Intelligence to the genetic sequence of patients to discover new therapies, announced today that is has raised $2.35M in its seed round. The investors include Third Kind Venture Capital (3KVC), Cosine, LLC ...
Read More »